2136633-23-1
Chemical Structure
Disitamab vedotin
Synonym(s): RC48
- CAS No.: 2136633-23-1
- Formula:N/A
- Molecular Weight:149000 (average)
SMILES: [Disitamab vedotin]
Biological Activity: Disitamab vedotin (RC48) is a HER2-targeted antibody-drug conjugate (ADC), formed by conjugation of the humanized anti-HER2 antibody Disitamab (HY-P99854) with drug-linker VcMMAE (HY-15575). VcMMAE consists of a cleavable MC-Val-Cit-PAB linker and the microtubule inhibitor MMAE (HY-15162). After binding to HER2 and undergoing endocytosis, Disitamab vedotin releases MMAE in lysosomes, which further inhibits microtubule assembly, arrests mitosis and induces apoptosis, while also exerting a bystander effect. Disitamab vedotin can be used in studies of HER2-positive breast cancer[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Disitamab vedotin | 99.06% | Disitamab vedotin (RC48) is a HER2-targeted antibody-drug conjugate (ADC), formed by conjugation of the humanized anti-HER2 antibody Disitamab (HY-P99854) with drug-linker VcMMAE (HY-15575). VcMMAE consists of a cleavable MC-Val-Cit-PAB linker and the microtubule inhibitor MMAE (HY-15162). After binding to HER2 and undergoing endocytosis, Disitamab vedotin releases MMAE in lysosomes, which further inhibits microtubule assembly, arrests mitosis and induces apoptosis, while also exerting a bystander effect. Disitamab vedotin can be used in studies of HER2-positive breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Deeks ED, et al. Disitamab Vedotin: First Approval. Drugs. 2021 Nov;81(16):1929-1935. [Content Brief]
- [2]. Huang L, et al. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast cancer research and treatment. 2022 Jan;191(1):51-61. [Content Brief]
- [3]. Shi F, et al. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug delivery. 2022 Dec;29(1):1335-1344.
- [4]. Wang J, et al. Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study. Cancer communications (London, England). 2024 Jul;44(7):833-851.
- [5]. Jiang J, et al. Preclinical safety profile of Disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicology Letters. 2019. [Content Brief]
